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Modification of Alternative Splicing of Mcl-1
Pre-mRNA Using Antisense Morpholino
Oligonucleotides Induces Apoptosis in Basal Cell
Carcinoma Cells
Jeng-Jer Shieh1,2, Kuang-Ting Liu1, Shi-Wei Huang1, Yi-Ju Chen3 and Tsu-Yi Hsieh1,4
Myeloid cell leukemia-1 (Mcl-1, Mcl-1L) is an anti-apoptotic protein of the Bcl-2 family that acts as a critical
molecule in apoptosis control. Mcl-1 pre-mRNA can undergo alternative splicing to yield the short isoform, Mcl-
1S, which resembles BH3-only pro-apoptotic proteins and induces apoptosis. Overexpression of Mcl-1 may play
a role in various human tumors, and Mcl-1 may serve as a target in cancer therapy. In this study, we found an
imbalance between the expression levels of Mcl-1L and Mcl-1S in the skin basal cell carcinoma (BCC) cell line
when compared with primary keratinocytes. We showed that overexpression of Mcl-1S induces apoptosis in
BCC cells. Finally, we showed that Mcl-1 antisense morpholino oligonucleotides (AMOs) can specifically target
Mcl-1 pre-mRNA and shift the splicing pattern from Mcl-1L to Mcl-1S mRNA and protein. This shift increases the
level of pro-apoptotic Mcl-1S and reduces the level of anti-apoptotic Mcl-1L, which induces apoptosis in BCC
cells and AGS cells, a human gastric adenocarcinoma epithelial cell line. Thus, this report provides a strategy for
cancer therapy in which AMOs change the alternative splicing pattern of Mcl-1 pre-mRNA and thereby induce
apoptosis.
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INTRODUCTION
Apoptosis—programmed cell death—plays significant roles
in the development and maintenance of tissue homeostasis
and in the pathogenesis of specific diseases (Thompson,
1995). The Bcl-2 family of proteins are key regulators of
apoptotic and survival control (Cory and Adams, 2002). The
Mcl-1 gene, an anti-apoptotic member of the Bcl-2 family,
contains three exons and encodes a polypeptide of 350
amino acids (Mcl-1 or Mcl-1L, 42 kDa) that shows 35%
homology with the C-terminus of the Bcl-2 protein (Kozopas
et al., 1993). The Mcl-1 protein possesses the Bcl-2 homology
domain 1 (BH1), BH2, BH3, and transmembrane domains
found in other Bcl-2 family of proteins, and it also contains a
unique PEST sequence in the N-terminal region commonly
found in rapid turnover proteins (Yang et al., 1995). The
transcription of the Mcl-1 gene is highly regulated by survival
and differentiation signaling pathways such as mitogen-
activated protein kinase, phosphatidylinositol-3 kinase, and
Janus kinase/signal transducer and activator of transcription,
through specific cytokine- and growth-factor receptors
(Michels et al., 2005; Yang-Yen, 2006). The Mcl-1 mRNA
has a short half-life and the rapid degradation of the Mcl-1
protein by proteasomes suggests that it plays a crucial role in
survival or apoptotic control in response to rapidly changing
environmental cues (Yang et al., 1996). Mcl-1 is essential for
embryogenesis (Rinkenberger et al., 2000) and for the
development and maintenance of specific leukocytes in
animals (Moulding et al., 1998; Opferman et al., 2003). It is
upregulated in many human malignant cells, and down-
regulation of Mcl-1 expression by antisense inhibition has
been reported to enhance apoptosis in some tumor cell lines
(Mandelin and Pope, 2007; Warr and Shore, 2008). Thus,
Mcl-1 may be not only a useful prognostic/predictive marker
but also a therapeutic target for cancer treatment.
The Mcl-1 pre-mRNA undergoes alternative splicing by
eliminating exon 2 and is referred to as Mcl-1S (30 kDa)
(Bingle et al., 2000). Mcl-1S contains 271 amino acids and
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has 41 residue differences at C-terminus as compared
with Mcl-1L. Mcl-1S has only a BH3 domain, similar to the
BH3-only pro-apoptotic proteins, and it can selectively
dimerize with Mcl-1L (Bae et al., 2000). Overexpression of
Mcl-1S can antagonize the anti-apoptotic effect of Mcl-1L
and promote cell apoptosis (Bae et al., 2000; Bingle et al.,
2000). The upregulation of Mcl-1S may contribute to human
trophoblast apoptosis induced by hypoxia in preeclampsia
and may also mediate apoptosis in some cancer cells treated
by several anti-cancer compounds (Huang et al., 2004;
Soleymanlou et al., 2007). These findings suggest that the
Mcl-1 gene generates a Bcl-2-like anti-apoptotic Mcl-1L and
BH3-only pro-apoptotic Mc1-1S. The fate of Mcl-1-expres-
sing cells may be regulated through alternative splicing
mechanisms and interactions of the resulting Mcl-1L and
Mcl-1S proteins. Thus, we hypothesized that cancer cells and
normal cells may have differential expression of Mcl-1L and
Mcl-1S. Disturbing the Mcl-1L expression in cells by down-
regulating Mcl-1L and/or overexpressing Mcl-1S may switch
the growth conditions from anti-apoptotic to pro-apoptotic
status and may induce apoptosis or increase the sensitivity of
cells to apoptotic reagents.
Antisense oligonucleotides have shown great promise in
research as sequence-specific agents able to downregulate
the expression of specific genes by complementing the target
mRNA, and thereby either blocking its translation or
triggering its degradation by RNase H (Sahu et al., 2007).
Antisense oligonucleotide approaches have also been devel-
oped to modify the splicing patterns of pre-mRNA (Schmajuk
et al., 1999; Sazani and Kole, 2003). Antisense oligonucleo-
tides have been designed to target specific cis elements in
pre-mRNA to correct abnormal splicing brought on by
splicing mutations in some genetic diseases, or to modulate
the expression of mRNA by changing the ratio of naturally
occurring splice variants (Wood et al., 2007; van Ommen
et al., 2008). Antisense morpholino oligonucleotides (AMOs),
which are one of the major systems of chemically modified
antisense oligonucleotides, have been applied to modify the
alternative splicing pattern of genes (Schmajuk et al., 1999).
They present a number of advantages including the fact that
they are DNA analogs and therefore are resistant to
enzymatic degradation; they show low toxicity, long-term
activity, and excellent target specificity. Given these char-
acteristics, we set out to use AMOs to specifically knock out
exon 2 within the Mcl-1 pre-mRNA, simultaneously reducing
expression of Mcl-1L and increasing expression of Mcl-1S,
thereby promoting cellular apoptosis.
In this study, we compared the expression levels of
Mcl-1L and Mcl-1S between the established human basal
cell carcinoma (BCC) cell line and primary human keratino-
cytes (PHKs), and we found the Mcl-1L expression to
predominate in the BCC cell line. We showed that over-
expression of Mcl-1S induced apoptosis of BCC cells. Finally,
we demonstrate a strategy for cancer therapy that to our
knowledge has not previously been reported, one that uses
Mcl-1 AMOs to change the alternative splicing pattern of
Mcl-1 pre-mRNA and promote apoptosis of BCC cells and
AGS cells.
RESULTS
Comparison of expression levels of Mcl-1L and Mcl-1S between
a BCC cell line and primary human keratinocytes
Cultured BCC cells have been shown to significantly over-
express IL-6, and its overexpression enhances tumor potency
by increasing anti-apoptotic activity through upregulation of
Mcl-1 gene expression (Yen et al., 1996; Jee et al., 2002).
Thus, Mcl-1 may play a role in the survival and apoptosis
programs of BCC cells. In this study, we propose that the
relative expression levels of Mcl-1L and Mcl-1S may differ
between BCC cell lines and their normal counterparts, PHKs.
To examine this hypothesis, we used reverse transcripta-
se–PCR analysis and immunoblot to distinguish between the
Mcl-1L and Mcl-1S expression in a BCC cell line and in
PHKs. As shown in Figure 1b, BCC cells expressed relatively
higher amounts of Mcl-1L mRNA and lower amounts of Mcl-
1S mRNA. Compared with BCC cells, PHK cells expressed
relatively lower amounts of Mcl-1L mRNA and higher
amounts of Mcl-1S mRNA. However, the mRNA pattern of
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Figure 1. The differential expression of the Mcl-1 splice variants Mcl-1L and
Mcl-1S in a basal cell carcinoma (BCC) cell line and in primary human
keratinocytes (PHKs). (a) Reverse transcriptase–PCR strategy to distinguish the
mRNAs of the Mcl-1 variants, and the strategy involving Mcl-1 antisense
morpholino oligonucleotides (Mcl-1 AMOs) to modify alternative splicing
pattern of Mcl-1 pre-mRNA. The primers (short arrows) for distinguishing the
transcripts of Mcl-1L and Mcl-1S were located at exons 1 and 3. The size of
PCR fragments of Mcl-1L and Mcl-1S transcripts was 1005 and 757bp,
respectively. The pairs of Mcl-1 AMOs target the 30 acceptor and 50 donor
splice sites flanking exon 2 of the Mcl-1 pre-mRNA, and they induce a shift in
splicing from Mcl-1L to Mcl-1S. The thin line indicates the Mcl-1L splicing
pathway. The dotted line indicates the splicing pathway for Mcl-1S mRNA.
Boxes indicate exons; thick lines, introns; solid gray boxes, the protein-coding
region; and thick bars below the pre-mRNA, Mcl-1 AMOs. (b) Different
relative expression of Mcl-1L and Mcl-1S mRNAs in BCC cell line and PHKs.
Reverse transcriptase–PCR using Mcl-1-specific primers resulted in PCR
products of 1005 and 757bp, representing Mcl-1L and Mcl-1S transcripts,
respectively. (c) The differential expression of Mcl-1L and Mcl-1S proteins in
the BCC line and PHKs was detected by immunoblot using anti-human Mcl-1
polyclonal antibodies. The 41- and 35-kDa bands represent Mcl-1L and
Mcl-1S proteins, respectively.
2498 Journal of Investigative Dermatology (2009), Volume 129
J-J Shieh et al.
Modification of Mcl-1 Splicing Induces Apoptosis
Mcl-1 variants was similar in BCC cells, which were grown in
regulator medium or serum-free keratinocyte growth medium
(Figure S1). This result indicated that the prominent expres-
sion of Mcl-1L mRNA and reduced expression of Mcl-1S
mRNA in BCC cells were consistent and did not result from
different culture systems. Consistent with this difference in
the mRNA level, BCC cells expressed relatively higher
amounts of Mcl-1L protein than did PHK cells, whereas
PHK cells expressed relatively higher levels of Mcl-1S protein
(Figure 1c). These findings indicate that the transformed BCC
cell line differs from its normal counterparts in the relative
amounts of Mcl-1L and Mcl-1S that are expressed.
Overexpression of Mcl-1S induces apoptosis in BCC cells
The prominent expression of Mcl-1L and reduced expression
of Mcl-1S in BCC cells suggest that these BCC cells have
increased anti-apoptotic activity. We speculated that over-
expressing Mc1-1S in BCC cells would disrupt the functional
dominance of Mcl-1L, and perhaps switch the cells to a pro-
apoptotic state. We transfected and overexpressed untagged
or N-terminal FLAG-tagged Mcl-1S in BCC cells to explore
the pro-apoptotic role of Mcl-1S. As shown in Figure 2a, the
untagged Mcl-1S and FLAG-tagged Mcl-1S were overex-
pressed in BCC cells at 24 hours after transfection. Although
transfection efficiency was similar and comparable for the
two forms of Mc1-1S, cells expressed significantly higher
amounts of FLAG-tagged Mcl-1S than of untagged Mcl-1S. It
is interesting that, in the same blot, reduced amounts of the
Mcl-1L protein were detected in BCC cells overexpressing
FLAG-tagged Mcl-1S. Consistent with the blotting results,
BCC cells transfected with Mcl-1S showed stronger fluores-
cence signals when stained with an anti-Mcl-1 polyclonal
antibody (Figure 2b). The nontransfected cells showed a
relatively lower Mcl-1 background. The overexpressing Mcl-
1S signal co-localized with Mitotracker, a mitochondria-
specific fluorescent probe. It is surprising that the striking
fluorescence signal was observed in nuclei of cells trans-
fected with FLAG-tagged Mcl-1S and stained with an anti-
FLAG monoclonal antibody.
We evaluated the effects of overexpression of Mcl-1S on
sub-diploid DNA content in BCC cells. As shown in Figure 3,
the population of sub-G1 apoptotic cells was detected in
BCC cells transfected with either Mcl-1S or FLAG-tagged
Mcl-1S. The increase in the number of apoptotic cells was
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Figure 2. The overexpression of untagged Mcl-1S and FLAG-tagged Mcl-1S in basal cell carcinoma (BCC) cells. (a) BCC cells were transfected with either
pcDNA3.1, pcDNA3.1-Mcl-1S, or pcDNA3.1-FLAG-Mcl-1S and assayed 24 hours later for Mcl-1S expression by immunoblot using anti-human
Mcl-1 polyclonal antibody. The plasmid pEGFP was used as a transfection marker. The 41- and 35-kDa bands represent Mcl-1L and Mcl-1S proteins,
respectively. The electrophoretic mobility of Mcl-1S has been noted to be slower than its predicted molecular mass (29.4 kDa). The position of the
immunoreactive proteins smaller than 35 kDa, as indicated by the asterisks, may represent a proteolytic fragment of Mcl-1L. (b) BCC cells were transfected
with the pcDNA3.1-Mcl-1S expression construct or with pcDNA3.1-FLAG-Mcl-1S. After transfection, live cells were stained with Mitotracker Red CMXRos.
The cells were fixed and stained with rabbit polyclonal anti-Mcl-1 antibody or mouse monoclonal anti-FLAG antibody, and then stained with FITC-conjugated
anti-rabbit IgG or FITC-conjugated anti-mouse IgG, respectively. Note the intracellular co-localization of Mcl-1S with Mitotracker, indicated by yellow in the
merged image. Bars¼ 50mm.
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proportional to the time of transfection in both groups.
Furthermore, the cells transfected with FLAG-tagged Mcl-1S
showed more apoptotic potential than did cells transfected
with Mcl-1S, and this may be consistent with the fact that
FLAG-tagged Mcl-1S was expressed at higher levels in
transfected BCC cells than was in untagged Mcl-1S. Taken
together, these results show that overexpressing Mcl-1S
induces apoptosis in BCC cells that express higher levels of
endogenous Mcl-1L.
Delivery of morpholino oligonucleotides into BCC cells
The results described above indicate that exogenous Mcl-1S
not only counteracts the anti-apoptotic activity of Mcl-1L but
also induces apoptosis in BCC cells. Thus, modifying the
alternative splicing of Mcl-1 pre-mRNA may disrupt the
dominance of Mcl-1L expression in BCC cells. We hypothe-
sized that blocking the 30 acceptor and 50 donor sites of exon
2 with antisense oligonucleotides would cause the skipping
of exon 2 and thereby shift splicing from Mcl-1L to Mcl-1S
mRNA. Such a shift would reduce the level of the anti-
apoptotic Mcl-1L protein and increase the level of the pro-
apoptotic Mcl-1S protein.
To optimize the conditions for the delivery of AMOs, we
used the Endo-Porter delivery system and fluorescein-tagged
morpholino oligonucleotides, under different conditions. Re-
sults indicated that Endo-Porter efficiently delivered fluores-
cein-tagged morpholino oligonucleotides into BCC cells
(Figure 4). The number of transfected BCC cells showing
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Figure 3. Transfection with the Mcl-1S variant results in cell death of the basal cell carcinoma (BCC) cell line. BCC cells were transfected with either
pcDNA3.1-Mcl-1S or pcDNA3.1-FLAG-Mcl-1S. The apoptotic cells with sub-G1 phase were examined by PI-FACS analysis at 24, 48, and 72 hours after
transfection. The cells transfected with pcDNA3.1 served as a control.
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Figure 4. Endo-Porter delivery of fluorescein-tagged morpholino oligonucleotide into basal cell carcinoma (BCC) cells. Delivery efficiencies of
fluorescein-tagged morpholino oligonucleotides (F-M. oligo.) by Endo-Porter were determined using fluorescence microscopy. Fluorescence signal showed
delivery of the fluorescein-tagged morpholino oligonucleotides inside live nonfixed cells and also showed a high level of transfection efficiency after 24 hours;
the amount of fluorescence in cells increased with the amount of Endo-Porter and morpholino oligonucleotides used. Bars¼50 mm.
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fluorescence increased with the amount of Endo-Porter delivery
reagent and with the amount of fluorescein-tagged morpholino
oligonucleotides. Cell cultures treated with the morpholino
oligonucleotides (30mM) and with Endo-Porter (10mM) for
24hours resulted in an 80% transfection efficiency. To ensure
that our results did not reflect toxicity effects, we examined the
cytotoxicity of Endo-Porter in BCC cells. We observed no
significant cytotoxicity in BCC cells incubated with different
concentrations of Endo-Porter for 24hours. Cytotoxicity in BCC
cells was, however, observed in a dose-dependent manner after
incubation for 36hours (data not shown).
Antisense morpholino oligonucleotides that shift the splicing
pattern of Mcl-1 pre-mRNA from Mcl-1L to Mcl-1S
Mcl-1-specific AMOs (Mcl-1 AMOs) were designed to target
the 30 acceptor and 50 donor splice site boundaries flanking
exon 2 of the Mcl-1 pre-mRNA sequence (Figure 1a). We
reasoned that the steric blocking of these splice sites would
inhibit the binding of trans-splicing regulatory proteins
necessary for regular splice-site recognition and thereby
prevent inclusion of exon 2 in Mcl-1 mRNA. As shown in
Figure 5a, BCC cells treated with Mcl-1 AMOs for 24 hours
showed a significant reduction in the expression of Mcl-1L
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Figure 5. Shift in splicing from Mcl-1L to Mcl-1S after treatment of basal cell carcinoma (BCC) cells with Mcl-1 AMOs. (a) The effect of Mcl-1 AMOs on
expression of Mcl-1S splice variants was dose-dependent. BCC cells were treated with 10mM Endo-Porter and different concentrations of Mcl-1 AMOs for
24 hours. The results from the analysis of total cellular RNA using reverse transcriptase–PCR are shown. The lengths of the PCR products (in base pairs) are
indicated on the right. (b) The time course of the shift in splice pattern from Mcl-1L to Mcl-1S after treatment of BCC cells with Mcl-1 AMOs. RNA was isolated
from cells transfected with paired Mcl-1 AMOs (total concentration of 30mM) at 4, 8, 12, 18, 24, and 36 hours after transfection. The results from the analysis
of total cellular RNA by reverse transcriptase–PCR are shown. Control morpholino oligonucleotides (30 mM, Con. AMO) were delivered into cells using 10mM
Endo-Porter, and the Mcl-1 splicing pattern in BCC cells was analyzed by reverse transcriptase–PCR 24hours later. (c) The effect of Mcl-1 AMOs on Mcl-1L and
Mcl-1S protein expressions in BCC cells. The BCC cells were treated with 10mM Endo-Porter and 30 mM of paired Mcl-1 AMOs for 24 hours. Total cell lysates
were analyzed by immunoblot using antibodies against Mcl-1, Bcl-2, and Bcl-xL. (d) Disruption of mitochondrial potential in BCC cells treated with Mcl-1
AMOs. BCC cells were untreated or treated with 10 mM Endo-Porter alone or in combination with 30 mM Mcl-1 AMOs for 18 hours. The mitochondrial potential
was stained by JC-1 dye and measured using a fluorescence microplate reader. Data are expressed as relative ratio of red to green fluorescence. The level of JC-1
retained by untreated cells was considered to be 100%. (e) The shift of splicing from Mcl-1L to Mcl-1S by Mcl-1 AMO treatment could induce mitochondria-
mediated apoptosis in BCC cells. The BCC cells were treated with 10 mM Endo-Porter and 30 mM of paired Mcl-1 AMOs for 24 hours. Total cell lysates were
analyzed by immunoblot using antibodies against Bax, cleaved caspase 9, and cleaved PARP antibodies.
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mRNAs, as reflected by the decrease in the intensity of the
1005-bp PCR product and the appearance of a smaller 757-
bp PCR product, which corresponded to the Mcl-1S splice
variant in a dose-dependent manner. The Mcl-1S splice
variant was detected as early as 4 hours after treatment with
Mcl-1 AMOs; the level reached a maximum at 18 hours and
decreased after 24 hours of incubation (Figure 5b). It is worth
noting that only the 1005-bp PCR product was observed in
the untreated cells, the cells treated with Endo-Porter alone,
and the cells treated with Endo-Porter plus control morpho-
lino oligonucleotide. We also directly sequenced the 757-bp
PCR product after Mcl-1 AMOs treatment to confirm the
precision of the shift in splice pattern. The sequence of the
757-bp PCR product matched the sequence of the Mcl-1S
mRNA, including the joint region between exons 1 and 3
(Figure S2).
The ability of Mcl-1 AMOs to decrease the production of
Mcl-1L protein was then assessed by immunoblot using
protein lysates prepared from BCC cells treated for 18 hours
with Mcl-1 AMOs (Figure 5c). The results show that BCC cells
treated with Mcl-1 AMOs contained significantly lower levels
of Mcl-1L (41 kDa) than did untreated cells or cells treated
with Endo-Porter only, and showed a smaller protein
(35 kDa), indicating translation of the Mcl-1S. As expected,
the levels of Bcl-2 and Bcl-xL were not significantly affected
by treating BCC cells with Mcl-1 AMOs. It is important to
note that the reduction in the level of Mcl-1L protein and the
appearance of Mcl-1S protein correlated with an earlier
decrease in Mcl-1L mRNA and an increase in Mcl-1S mRNA,
respectively. Taken together, these results show that steric
blockade of the 30 acceptor and 50 donor splice sites flanking
exon 2 of the Mcl-1 pre-mRNA by Mcl-1 AMOs led not only
to the specific exclusion of exon 2 but also to the correct
joining of exons 1 and 3 in the endogenous Mcl-1 pre-mRNA.
As a result of this shift in splice pattern from Mcl-1L mRNA to
Mcl-1S mRNA, the level of anti-apoptotic Mcl-1L protein
decreases, whereas the level of pro-apoptotic Mcl-1S protein
increases.
Shift in splicing from Mcl-1L to Mcl-1S in BCC cells leads to cell
apoptosis
Next, we evaluated whether altering Mcl-1 pre-mRNA
alternative splicing by Mcl-1 AMOs could lead to an increase
in apoptosis in BCC cells. To test this hypothesis, we
analyzed apoptotic cells by sub-diploid DNA content and
annexin V staining. Treatment with Mcl-1 AMOs resulted in a
dose-dependent increase in the number of apoptotic cells.
Quantitation of the results showed that treatment with 10, 20,
and 30 mM of Mcl-1 AMOs led to BCC populations in which
19.8, 30.9, and 35.3% of cells had sub-diploid DNA content,
respectively (Figure 6a). These results were statistically
significant in comparison with untreated cells (6.5%), with
cells treated with Endo-Porter only (10.3%), and with cells
treated with control morpholino oligonucleotide (11.7%).
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Figure 6. Apoptosis of basal cell carcinoma (BCC) and AGS cells treated with Mcl-1 AMOs. (a) The effect of Mcl-1 AMOs on BCC cells apoptosis was dose-
dependent. Shown are the results from FACS analysis for the hypodiploid DNA content of BCC cells transfected for 24 hours with 10 mM Endo-Porter and different
concentrations of Mcl-1 AMOs or 30mM control antisense morpholino oligonucleotide (Con. AMO). (b) BCC cells were treated with 10 mM Endo-Porter alone or
in combination with either 30mM Mcl-1 AMOs or 30 mM Con. AMO for 18 hours, and apoptotic cells were determined by annexin V/IP dual staining. (c) The
effect of Mcl-1 AMOs on apoptosis of AGS cells was detected by FACS analysis for hypodiploid DNA content. (d) The effect of Mcl-1 AMOs on expression of
Mcl-1S splice variants in AGS cells was detected by reverse transcriptase–PCR. The AGS cells were untreated or treated with 10 mM Endo-Porter alone or in
combination with 30 mM Mcl-1 AMOs for 18 hours. Results are represented as mean±SD from three independent experiments.
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Treatment with Mcl-1 AMOs also resulted in an increase in
the number of annexin V-positive cells; at 30 mM of Mcl-1
AMOs, the effect (21.9%) was statistically significant relative
to untreated cells (7.8%), cells treated with Endo-Porter only
(7.6%), and control morpholino oligonucleotide-treated cells
(4.5%) (Figure 6b). In addition, after 18 hours of treatment
with Mcl-1 AMOs, the mitochondrial membrane potential
was significantly decreased in BCC cells (Figure 5d). The
amount of Bax, activated caspase 9, and cleaved PARP in
BCC cells was markedly elevated (Figure 5e). These results
indicated that the shift in splicing from Mcl-1L to Mcl-1S in
BCC cells by Mcl-1 AMOs induces cell apoptosis through the
mitochondrial apoptotic pathway.
It is necessary to prove the apoptotic effects of Mcl-1
AMOs in different cell lines. Evidences indicated that the
upregulation of Mcl-1L inhibits the apoptosis of AGS cells
(Lin et al., 2001), and significantly suppressed Mcl-1
expression by Mcl-1 siRNA could abolish the anti-apoptotic
effects in AGS cells (Pritchard et al., 2008). Thus, Mcl-1L may
also play a role in the survival of AGS cells. We chose this
cell line as another target cell to evaluate the apoptotic effects
of Mcl-1 AMOs. Similar to BCC cells, the Mcl-1 AMO
treatment not only shifted the splicing pattern from Mcl-1L to
Mcl-1S mRNA but also resulted in cell apoptosis in AGS cells
(Figure 6c and d). Thus, the apoptosis induced by Mcl-1
AMOs is not limited to a single BCC cell line. These results
further showed that this strategy could be applied to other
selective cancer cell lines in which Mcl-1L acts as a
therapeutic target for cancer treatment.
DISCUSSION
In this study, we compared the relative expression levels of
Mcl-1L and Mcl-1S between the established BCC cell line
and PHKs, and we found that these two cell types express the
Mcl-1 variants in different ratios. Next, we observed that
overexpression of Mcl-1S induces apoptosis in BCC cells.
Finally, we showed that Mcl-1 pre-mRNA can be specifically
targeted by Mcl-1 AMOs and that the splicing pattern can be
shifted from Mcl-1L to Mcl-1S mRNA. As a result of this shift,
the level of pro-apoptotic Mcl-1S protein increases, whereas
the level of anti-apoptotic Mcl-1L protein decreases. This shift
in the Mcl-1 splicing pattern was found to directly induce
apoptosis in BCC cells and AGS cells.
Mcl-1L has been reported to be a useful prognostic and
predictive marker for specific tumor development. Cultured
BCC cells secrete significant levels of IL-6, and the ectopic
expression of IL-6 in the BCC cell line increases anti-
apoptotic activity by upregulating Mcl-1L expression through
an autocrine mechanism (Jee et al., 2002). The Mcl-1S, a
short splice variant of Mcl-1, represents a BH3-only pro-
apoptotic protein capable of selectively dimerizing with Mcl-
1L, antagonizing the Mcl-1L function and inducing apoptosis
(Bae et al., 2000). Thus, the fate of BCC cells may be
regulated by a balance between the resulting anti- and pro-
apoptotic variants of the Mcl-1 gene. We observed that Mcl-
1L was overexpressed in cultured BCC cells. In contrast, the
expression of Mcl-1S was lower in BCC cells than in PHKs.
This result may explain the increase in anti-apoptotic potency
in the transformed BCC cell line, as Mcl-1 gene expression is
upregulated such that Mcl-1L expression is enhanced, but not
simultaneously, equally enhancing the expression of Mcl-1S
by alternative splicing. However, the primary keratinocytes
express much balanced Mcl-1L and Mcl-1S variants. Thus,
the balance between Mcl-1L and Mcl-1S may determine the
fate of cells, in which Mcl-1 plays a role for survival. The
possibility that this imbalance in BCC cells was due to
the stimulation of different culture systems is ruled out by the
observation that the expression pattern of Mcl-1 variants in
BCC cells was consistent in different mediums. Further studies
are needed to determine whether the cancerous and normal
parts in the same clinical BCC specimen also show different
expression patterns of Mcl-1 variants and to understand the
mechanisms regulating the alternative splicing of Mcl-1.
Overexpression of Mcl-1S has been shown to induce
apoptosis in Chinese hamster ovary and A549 cells (Bae
et al., 2000; Bingle et al., 2000). Here, we observed a similar
apoptotic effect of Mcl-1S in BCC cells. These results indicate
that Mcl-1S may antagonize the function of Mcl-1L and
induce apoptosis in various cells. In this study, we made
several interesting observations. First, the N-terminal FLAG-
tagged Mcl-1S was expressed at a higher level and had more
apoptotic potential than did cells transfected with untagged
Mcl-1S under similar transfection efficiency. One possibility
is that the N-terminal FLAG tag provides a perfect Kazak
sequence (50-tAccATGG-30) that is translated more efficiently
than the sequence of the untagged Mcl-1S (50-cAccATGT-30)
(Kozak, 1987). Second, there is evidence that the BH3-only
proteins that selectively bind to Mcl-1L protein, such as Noxa
and Ureb-1, may specifically target it for proteasomal
degradation (Warr et al., 2005; Czabotar et al., 2007). This
evidence may support our theory that a decrease in
endogenous Mcl-1L protein in BCC cells transfected with
tagged Mcl-1S occurs through a similar degradation process.
Third, although the Mcl-1S protein lacks a transmembrane
domain, its selective interactions with Mcl-1L may help Mcl-
1S to localize on the mitochondrial membrane. Using
immunocytochemistry with an anti-Mcl-1 polyclonal anti-
body, we observed that untagged Mcl-1S localized mainly on
mitochondria in transfected cells. In contrast, the remarkable
fluorescence signal of FLAG-tagged Mcl-1S not only co-
localized with Mitotracker but was also observed in the
nuclei when stained with an anti-FLAG monoclonal anti-
body. This result suggests that N-terminal proteolytic
fragments of tagged Mcl-1S containing FLAG epitope may
translocate to the nucleus. A proteolytic fragment of Mcl-1L
(snMcl-1) has been reported to translocate into the nucleus
and regulate cell growth (Jamil et al., 2005). Mcl-1L and Mcl-
1S share high identity along their sequence, except in their C-
terminal regions. Thus, it is possible that the N-terminal
proteolytic fragment of Mcl-1S also translocates to the
nucleus. The structure and function of Mcl-1S, and their
relationship to the sub-cellular localization, may merit further
study.
AMOs have been successfully used to splice out specific
exons in mammalian systems, for example, skipping specific
exons in dystrophin pre-mRNA in mdx mouse muscle (Gebski
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et al., 2003) and repairing a splicing defect in erythroid cells
with aberrant splicing of b (E)-globin pre-mRNA (Suwanma-
nee et al., 2002). These successes demonstrate the potent
application of AMOs in various diseases. Owing to the
uncharged nature of the morpholino backbone, we chose
Endo-Porter, an amphiphilic peptide delivery system, to
replace the conventional cationic lipid transfection system.
Endo-Porter delivers cargo into the cytoplasm via an
endocytosis-mediated process that avoids damaging the
plasma membrane of cells (Summerton, 2005). However,
we observed cytotoxicity of Endo-Porter at a high dose in
BCC cells after 36 hours of incubation. Many cell-permeable
peptides have been reported to induce dose-, time-, and
length-dependent cytotoxic effects (Cardozo et al., 2007).
This may be because these peptides strongly enhance
endocytosis, increasing cellular stress and promoting autop-
hagy-related cell death. However, we cannot rule out the
possibility that the cytotoxicity of Endo-Porter will differ
between BCC cells and other cells.
Knockdown of Mcl-1L by siRNA or by an antisense
oligonucleotide sensitizes various tumor cells to different
treatment regimens in vitro (Mandelin and Pope, 2007; Warr
and Shore, 2008). Transiently transfecting antisense Mcl-1
into an IL-6 overexpressed BCC cell line also strongly
enhanced the frequency of apoptosis after UV exposure,
although downregulation of Mcl-1 alone did not directly
induce apoptosis (Jee et al., 2001). The Mcl-1S is unique in its
domain structure and biological function compared with
other known splicing variants of the Bcl-2 family. It has been
pointed out that Mcl-1S is the only known splice variant of a
Bcl-2 family gene that has intrinsic pro-apoptotic activity and
that can dimerize with other variants of the same gene in cells
(Bae et al., 2000). In this study, we have taken advantage of
this unique property and succeeded in shifting the splice
pattern from Mcl-1L to Mcl-1S mRNA in BCC cells with
Mcl-1 AMOs treatment. This shift simultaneously reduced
the level of anti-apoptotic Mcl-1L and increased the level of
the pro-apoptotic Mcl-1S protein in BCC cells, leading
directly to cell apoptosis.
The Bcl-2 family of proteins are primary regulators of
mitochondria-mediated apoptosis. According to one pro-
posed model, the main function of anti-apoptotic Bcl-2s (for
example, Bcl-2, Bcl-xL, and Mcl-1L) is to sequester pro-
apoptotic Bcl-2s (for example, Bak and Bax) and prevent
them from permeabilizing mitochondria. The role of BH3-
only pro-apoptotic proteins is to bind to anti-apoptotic Bcl-2s
and prevent them from sequestering Bak and Bax (Willis
et al., 2007). The key steps in mitochondria-mediated
apoptosis are the release of cytochrome c into the cytosol
via mitochondrial outer membrane permeabilization and
activation of specific caspase cascade. In this study, the
mitochondria membrane potential reduction, caspase 9
activation, and the PARP cleavage in BCC cells after Mcl-1
AMOs treatment indicated that this cell death is mediated
through mitochondrial-mediated apoptosis. Thus, it is possi-
ble that shifting the Mcl-1 splicing pattern by Mcl-1 AMOs
may prevent the interaction of Mcl-1L with Bak and/or Bax
by simultaneously decreasing anti-apoptotic Mcl-1L and
increasing BH3-only pro-apoptotic Mcl-1S, which selectively
antagonizes Mcl-1L function, thereby preventing Mcl-1L from
sequestering Bak and/or Bax. We also detected a significant
increase in the amount of Bax protein (Figure 5e). Therefore,
it is possible that treatment with Mcl-1 AMOs may upregulate
Bax expression. The combined effects of the Bax increase and
the Mcl-1 splicing shift may elevate the level of active Bax.
Further studies are needed to determine the mechanism of
Bax upregulation and whether Bax and/or Bak are activated
by treatment with Mcl-1 AMOs.
In conclusion, this study has shown that AMOs designed
to target both the 30 acceptor and 50 donor sites of exon 2 in
the Mcl-1 pre-mRNA result in shifting the splice pattern from
Mcl-1L to Mcl-1S mRNA, thereby decreasing the level of anti-
apoptotic Mcl-1L protein and increasing the level of pro-
apoptotic Mcl-1S protein. This shift disturbs the prominent
expression of Mcl-1L and directly causes apoptosis, not only
in BCC cells but also in AGS cells. Therefore, it may be
feasible to apply this approach to other tumors in which Mcl-
1 is a therapeutic target as a highly specific and effective
strategy in cancer therapy.
MATERIALS AND METHODS
Cells and culture conditions
BCC cells (Yen et al., 1996) and AGS cells (ATCC CRL 1739; a
human gastric adenocarcinoma epithelial cell line) were cultured in
RPMI 1640 medium supplemented with 10% FCS. PHKs from freshly
excised neonatal foreskins were purchased from GIBCO (Carlsbad,
CA). PHK cells were maintained in flasks coated with type IV
collagen and cultured in a serum-free keratinocyte growth medium
(Clonetics, San Diego, CA).
Reverse transcriptase–PCR
Total RNA was isolated using Trizol reagent (Invitrogen, Carlsbad,
CA). First-strand cDNA was synthesized from total RNA using the
Sprint PowerScript PrePrimed Single Shots Kit (Clontech, Mountain
View, CA). PCR reactions were carried out on the cDNAs (35 cycles
at 94 1C for 30 seconds, 60 1C for 30 seconds, and 68 1C for 1minute)
using Titallium Taq DNA polymerase (Clontech). The pair of primers
for distinguishing the two transcripts of Mcl-1 was the following:
Mcl-1 forward, 50-GTTGGTCGGGGAATCTGCTA-30; and reverse,
50-AAATTAATGAATTCGGCCGG-30. The pair of b-actin primers
used was as follows: b-actin forward, 50-ATTGCCGACAGGATGCA
GAA-30; and reverse, 50-GCTGATCCACATCTGCTGGAA-30. All PCR
products were fractionated by 2% agarose gel electrophoresis and
were visualized with ethidium bromide.
Immunoblotting
Cells were harvested and whole-cell extracts were prepared with a
PRO-PREP protein extraction reagent (iNtRON, Taipei, Taiwan).
Protein samples (30 mg) were resolved by SDS-PAGE and transferred
to a polyvinylidene difluoride membrane by electroblotting. After
blocking, the blots were incubated overnight in phosphate buffered
saline Tween-20 (PBST) at 4 1C with antibodies against Mcl-1, Bcl-2,
Bcl-xL, Bax, activate caspase 9, cleaved PARP, or b-actin (Cell
Signaling Technology, Danvers, MA). After being washed with PBST,
the blots were incubated with the corresponding horseradish
peroxidase–coupled anti-rabbit or anti-mouse secondary antibody
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(Pierce Biotechnology, Rockford, IL). Proteins were visualized with
SuperSignal West Pico ECL reagents (Pierce Biotechnology), and
chemiluminescence was detected by exposing the membranes to
Kodak-X-Omat Films (Eastman Kodak, Rochester, NY). Levels of b-
actin signal were used to verify equal protein loading in each lane.
Plasmid construction and DNA transfection
Using PCR mutagenesis, we generated the Mcl-1S cDNA fragment
by eliminating exon 2 from the full-length human Mcl-1 (Mcl-1L)
cDNA and retaining the open reading frame of Mcl-1S. In addition, a
FLAG tag was added to the N-terminus of Mcl-1S. The untagged or
tagged Mcl-1S cDNAs were ligated into the BamHI and XbaI sites of
pcDNA3.1 vectors to generate pcDNA3.1-Mcl-1S and pcDNA3.1-
FLAG-Mcl-1S. BCC cells were transfected with 4 mg of each
construct using Lipofectamine 2000 (Invitrogen). After 24 hours of
transfection, immunoblot, immunocytochemistry, and DNA content
analysis were used to confirm the expression of transfected Mcl-1S
and its potential to induce apoptosis.
Immunocytochemistry
Cells (5 104 cells per chamber) were cultured on two-chamber slides
(Nalgene Nunc International, Naperville, IL), transfected, and then
stained with Mitotracker Red CMXRos (Molecular Probes, Carlsbad,
CA). The transfected cells were fixed in 3.7% formaldehyde in a
phosphate-buffered saline (PBS). For intracellular staining, the cells
were blocked with 2% normal horse serum, incubated with antibodies
against FLAG tag (Sigma, St Louis, MO), or Mcl-1 (Cell Signaling
Technology) in PBS containing 0.2% Triton X-100 (PBST), and, finally,
incubated with goat FITC-conjugated anti-mouse IgG or FITC-
conjugated anti-rabbit IgG (Sigma). After a washing in PBST, the cells
were mounted using an anti-fade, water-based mounting medium
(Vector Lab, Burlingame, CA) and analyzed under a fluorescence
microscope (Leica TCS-4D DMIRBE, Heidelberg, Germany).
Morpholino oligonucleotides and delivery systems
All morpholino oligonucleotides and the Endo-Porter delivery
system were synthesized and purchased from Gene Tools (Philo-
math, OR). A pair of Mcl-1 AMOs was designed to splice out exon 2
of the Mcl-1L pre-mRNA by targeting two splice-site boundaries
flanking exon 2 (Figure 1a). The sequences of Mcl-1 AMOs for the 30
acceptor and 50 donor-splicing site of exon 2 were 50-CGAAGC
ATGCCTGAGAAAGAAAAGC-30 and 50-AAGGCAAACTTACCCAG
CCTCTTTG-30, respectively. The control morpholino oligonucleo-
tide was used as a nonspecific control, and it had the sequence
50-CCTCTTACCTCAGTTACAATTTATA-30. Fluoresceinated control
morpholino oligonucleotides were used to optimize the delivery
efficiency of the Endo-Porter system in the BCC cell line by
calculating the relative numbers of fluorescence-positive cells within
defined fields using fluorescence microscopy. Experiments applying
the Endo-Porter delivery system used 6–10mM of the Endo-Porter
solution and 5–30 mM of the morpholino preparations in RPMI 1640
medium containing 2% fetal calf serum.
Mitochondrial membrane potential measurement
Cells were incubated with a medium containing 1 mgml1 JC-1
(Molecular Probe) for 37 1C, washed with PBS, and then measured
with a fluorescence microplate reader (Biotek, Winooski, VT), with
an excitation wavelength of 485 nm and an emission wavelength of
535 nm, as well as with an excitation wavelength of 560 nm and an
emission wavelength of 595 nm. Mitochondrial membrane potential
was expressed as the ratio of emission at 595 nm to that at 535 nm.
DNA content assay
BCC cells transfected with plasmids or morpholino oligonucleotides
were harvested at the indicated time and fixed in 70% ethanol at
4 1C. After centrifugation (300 g), the cell pellets were resuspended
in a buffer containing 0.5% Triton X-100/PBS, 0.05% RNase A, and
50 mgml1 propidium iodide (PI) at 37 1C for 30min. After staining,
the cells were collected and resuspended in PBS. Fluorescence
emitted from PI-DNA complexes after laser excitation of the
fluorescent dye was quantified using the Cytomics FC500 Flow
Cytometer (Beckman Coulter, Fullerton, CA).
Annexin-V/propidium iodide (PI) staining assay
BCC cells (2 106 cells per dish) were seeded into 6-cm dishes
overnight, followed by morpholino oligonucleotide delivery. The
treated cells were washed with PBS, trypsinized, and resuspended in
a binding buffer. The cells were then stained with annexin V-FITC
and PI for 15minutes in the dark and diluted with the binding buffer
to a final volume of 600ml using the ApopNexin FITC Apoptosis
Detection kit (Chemicon, Billerica, MA). A total of 10,000 cells were
acquired per sample. Data acquisition and analysis were carried out
on a Cytomics FC500 Flow Cytometer (Beckman Coulter).
Statistical analysis
Three independent experiments were conducted in all studies, and
all assay conditions were performed in duplicate or triplicate. Data
were analyzed using Student’s t-test, and a P-value of 0.05 or less
was defined as the threshold for significant differences.
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SUPPLEMENTARY MATERIAL
Figure S1. The expression patterns of Mcl-1 variants in BCC cells, which are
grown in regulator medium or in serum-free keratinocyte growth medium
(KGM) at 24 and 48 hours, were detected by reverse transcriptase–PCR.
Figure S2. The precision with which exon 2 of Mcl-1L was eliminated from
the processed mRNA using Mcl-1 AMOs was examined by direct sequencing.
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